MH048

MH048 is a novel, non-covalent inhibitor of Bruton's tyrosine kinase (BTK), including both wild-type and C481S-mutant forms. It is being developed for the treatment of relapsed or refractory B-cell malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), and diffuse large B-cell lymphoma (DLBCL). In early-phase clinical trials, MH048 demonstrated good tolerability and preliminary efficacy in heavily pre-treated patients with B-cell malignancies. The drug shows dose-proportional pharmacokinetics and is administered once daily. The recommended doses for expansion are 135 mg and 200 mg once daily[1][2][3][4].